January 17, 2024- To optimize clinical manufacturing processes for innovators developing breakthrough cell therapies, Thermo Fisher Scientific announced the launch of the Gibco™ Cell Therapy Systems (CTS™) Cellmation™ Software, a first-of-its-kind automation solution designed to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance. This new offering can help eliminate the need for costly custom software projects and extensive validation, saving valuable time and resources during the cell therapy manufacturing process and helping to deliver these promising curative therapies more quickly and safely to patients.
The cell therapy manufacturing process is estimated to include upwards of 40 manual touchpoints, increasing opportunities for errors and contamination that can lead to failure and delay potentially life-saving treatment for those who need it most. The CTS Cellmation Software, powered by Emerson’s DeltaV™ Distributed Control System (DCS), connects Thermo Fisher’s cell therapy instruments within a single, user-friendly interface, reducing the number of manual touchpoints required. By establishing an automated workflow across multiple stages of cell therapy manufacturing, CTS Cellmation Software helps enable traceability, repeatability and 21 CFR Part 11 compliance with secured data connectivity.